Zura Bio (NASDAQ:ZURA) Shares Down 5.3% – Time to Sell?

Zura Bio Limited (NASDAQ:ZURA)’s share price was down 5.3% during trading on Monday . The company traded as low as $5.50 and last traded at $5.5040. Approximately 368,677 shares traded hands during trading, a decline of 44% from the average daily volume of 656,613 shares. The stock had previously closed at $5.81.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ZURA shares. Oppenheimer decreased their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. Wedbush initiated coverage on shares of Zura Bio in a research note on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research note on Wednesday, April 8th. Finally, Chardan Capital increased their price objective on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Trading Down 7.5%

The firm has a market cap of $510.08 million, a price-to-earnings ratio of -5.08 and a beta of 0.24. The company has a fifty day moving average price of $6.19 and a 200-day moving average price of $5.05.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31). As a group, research analysts forecast that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Zura Bio

In other news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the transaction, the insider owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.23% of the company’s stock.

Institutional Trading of Zura Bio

Several institutional investors have recently bought and sold shares of ZURA. Bank of America Corp DE grew its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the period. AQR Capital Management LLC acquired a new position in Zura Bio during the first quarter worth $72,000. JPMorgan Chase & Co. raised its position in Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares during the period. Jane Street Group LLC acquired a new position in Zura Bio during the second quarter worth $113,000. Finally, Forefront Wealth Partners LLC acquired a new stake in Zura Bio in the 3rd quarter worth about $93,000. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.